The Patent Finder
KB

Kinnate Biopharma Inc.

First filing 2019
OverviewNotableFeesChangesFamiliesPatent listSources & methods

1 patent currently held

15 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Jun 2041. from the record

Of the 15 now held by other companies, 10 name Pierre Fabre Médicament SAS as their current owner, and 5 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jun 2041
Next term end
1
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.

Formerly held, still cited

Notable
The most cited patent in this portfolio, cited by 7 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2040.
Ends Oct 2040 · High confidence
Also notable
Cited by 5 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2040. A terminal disclaimer caps this term to an earlier patent's.
Ends Apr 2040 · High confidence
Also notable
The newest of the three, granted 2023. It anchors the portfolio to 2043, later than anything else here.
Ends Feb 2043 · High confidence

Fee deadlines

No maintenance fee falls due on this company's record before Nov 17, 2027.

Recent changes

  • 1 term has ended since Aug 20, 2026

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 1 of 1

PatentTitleStatusExpiresConfidence
US 11,345,681Inhibitors of Fibroblast Growth Factor Receptor Kinases
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 1: 15 patents in force now held by others · 4 patents ended · 6 applications pending · 6 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
4 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited